-L Catley Researcher Activity Profile

Research Author Detailed Information 

L Catley Publication Rate By Year

L Catley has published 3 paper(s) in 2006, 8 paper(s) in 2007, 2 paper(s) in 2008, for a total of 13 research publications in total.

L L Catley Author Information

LAST NAME: catley

FIRST NAME: L

INITIALS: l

AFFILIATION:

Papers

L Catley's Publication Record

1. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Year Published: 2006
Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA.
2. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Year Published: 2006
Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.
3. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Year Published: 2006
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA. Ellen_weisberg@dfci.harvard.edu
4. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA. kenneth_anderson@dfci.harvard.edu
5. Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass., USA. laurence.catley@mater.org.au
6. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
7. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Year Published: 2007
Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.
8. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
9. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
10. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
11. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
12. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Year Published: 2008
13. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Year Published: 2008
Department of Medical Oncology/Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA 02115, USA.